Latin America Research Stats
Applied Clinical Trials
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe.
Starting with Eastern European sites in the 1990s, companies have increasingly selected investigator sites outside of North America and Western Europe. Recently, drug development organizations have also been recruiting sites and enrolling patients in more remote locations such as Asia, India, and Latin America. Little research has been done on the attitudes of investigators in these newer geographies: why they participate in clinical trial research, what they like and dislike about their clinical trial experiences, and their thoughts about organizations conducting these clinical studies. TTC and the University of the Sciences in Philadelphia conducted a 4,000 multinational site survey.
The overall response distribution in Latin America closely followed the distribution of sites by country and therapeutic areas recorded in ClinicalTrials.gov. The complete questionnaire and respondent answers can be found online.
Latin America and US investigators emphasize the importance of medical innovation as grounds for their involvement in clinical studies. For Latin American physicians, this interest in innovation holds whether the research directly touches their patients or not. Latin American investigators are especially keen to share their clinical trial derived knowledge with other physicians.
—TTC and the University of Sciences in Philadelphia (for more information, contact help@ttc-llc.com).
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
